| scholarly article | Q13442814 |
| P50 | author | Laura J. Havrilesky | Q87009294 |
| Bradley J. Monk | Q107013145 | ||
| David E. Cohn | Q39381089 | ||
| P2093 | author name string | Robert A Burger | |
| Evan R Myers | |||
| Lari Wenzel | |||
| J Michael Straughn | |||
| Jason C Barnett | |||
| P2860 | cites work | What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? | Q80944346 |
| Cancer statistics, 2014 | Q27861018 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study | Q30411910 | ||
| Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study | Q30415018 | ||
| Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q30438803 | ||
| Are pharmaceuticals cost-effective? A review of the evidence. | Q33863325 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| EQ-5D: a measure of health status from the EuroQol Group | Q34086093 | ||
| Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? | Q34166892 | ||
| Erlotinib in lung cancer - molecular and clinical predictors of outcome | Q34559274 | ||
| Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial | Q36680034 | ||
| Cost considerations in the treatment of colorectal cancer | Q36870003 | ||
| Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer | Q43160178 | ||
| At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis | Q43865208 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer | Q45800725 | ||
| Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer | Q46919795 | ||
| Reliability and validity of the functional assessment of cancer therapy-ovarian. | Q51068823 | ||
| Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - general. | Q51909975 | ||
| Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. | Q53176298 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 293-299 | |
| P577 | publication date | 2014-10-23 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer | |
| P478 | volume | 136 |
| Q51099700 | Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. |
| Q60931043 | Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| Q28076188 | Bevacizumab in ovarian cancer: A critical review of phase III studies |
| Q55366217 | Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. |
| Q99628789 | Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer |
| Q91339035 | Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy |
| Q52598812 | First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis. |
| Q90695877 | Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer |
| Q92397942 | Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer |
| Q51369186 | Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. |
| Q38384654 | Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review |
| Q38529445 | Why have ovarian cancer mortality rates declined? Part II. Case-fatality |
Search more.